- 1 Relative vaccine effectiveness (rVE) of mRNA COVID-19 boosters in the UK vaccination
- 2 programme, during the Spring-Summer (monovalent vaccine) and Autumn-Winter 2022
- 3 (bivalent vaccine) booster campaigns: a prospective test negative case-control study
- 4 Dr Anastasia Chatzilena PhD†, Engineering Mathematics, University of Bristol, Bristol, UK
- 5 Dr Catherine Hyams PhD†, Population Health Sciences, University of Bristol, Bristol, UK
- 6 Dr Rob Challen PhD, Engineering Mathematics, University of Bristol, Bristol, UK
- 7 Dr Robin Marlow PhD, Population Health Sciences, University of Bristol, Bristol, UK
- 8 Ms Jade King MSc, Clinical Research and Imaging Centre, UHBW NHS Trust, Bristol, UK
- 9 Mr David Adegbite BSc, Bristol Vaccine Centre, Population Health Sciences, University of
- 10 Bristol, Bristol, UK
- 11 Ms Jane Kinney BSc, Bristol Vaccine Centre, Population Health Sciences, University of Bristol,
- 12 Bristol, UK
- 13 Ms Madeleine Clout BSc, Bristol Vaccine Centre, Population Health Sciences, University of
- 14 Bristol, Bristol, UK
- 15 Prof Nick Maskell MD, Academic Respiratory Unit, University of Bristol, Southmead Hospital,
- 16 Bristol, UK

- 17 Dr Jennifer Oliver PhD, Bristol Vaccine Centre, Population Health Sciences, University of
- 18 Bristol, Bristol, UK
- 19 Professor Adam Finn PhD†, Bristol Vaccine Centre, Cellular and Molecular Medicine and
- 20 Population Health Sciences, University of Bristol, Bristol, UK
- 21 Dr Leon Danon PhD†, Engineering Mathematics, University of Bristol, Bristol, UK
- 22 (Corresponding Author)
- 23 The Avon CAP Research Group
- † These authors contributed equally, and should be considered co-first or last authors
- 26 Corresponding Author: Leon Danon, PhD
- 27 Engineering Mathematics, University of Bristol

¹ NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28		University Walk
29		Bristol BS8 1TW
30		United Kingdom
31		+44(0)117 455 7828
32		l.danon@bristol.ac.uk
33		
34	Keywords:	COVID-19, SARS-CoV-2, respiratory infection, vaccination

ABSTRACT (241/250 words) **Background** Understanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is an urgent public health priority. A precise comparison of the rVE of monovalent and bivalent boosters given during the 2022 Spring-Summer and Autumn-Winter campaigns, respectively, in a defined population has not been reported. We therefore assessed rVE against hospitalisation for the Spring-Summer (fourth vs third monovalent mRNA vaccine doses) and Autumn-Winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. Methods A prospective single-centre test-negative design case-control study of \geq 75 year-olds hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, gender, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. **Results** 682 controls and 182 cases were included in the Spring-Summer booster analysis; 572 controls and 152 cases for the Autumn-Winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed rVE 46.9% (95% confidence interval [CI] 14.4-67.3) versus those not boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had rVE 46.4% (95%CI 17.5-

65), compared to a fourth monovalent mRNA COVID-19 vaccine dose.

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

Interpretation

Both fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offer equivalent protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support the current UK immunisation programme that advises the use of bivalent booster doses.

INTRODUCTION

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

Following the emergence of wild-type SARS-CoV-2 and circulation of antigenically distinct variants, large-scale vaccination programmes were implemented to reduce overall COVID-19 morbidity and mortality. In the UK, several COVID-19 vaccines received rapid regulatory authorisation: the vaccines used initially were the monovalent mRNA vaccine BNT162b2 (Cominarty®) and the ChAdOx1 (Vaxzevria®) replication-deficient simian adenovirus vector vaccine, with mRNA-1273 (Spikevax®) vaccine incorporated a few months later. These three COVID-19 vaccines were used in the primary campaign, with the mRNA vaccines offered as boosters from September 2021 for older people, extending to all adults in November 2021. A fourth dose of an mRNA vaccine was offered from March 2022 and prioritised the most vulnerable: all adults aged ≥ 75 years (y), and those in clinical risk groups[1]. A third priming vaccine dose had already been offered to immunosuppressed individuals, so that for them, the autumn 2021 and spring 2022 boosters were generally their fourth and fifth doses, respectively. The COV-Boost study indicated that a fourth-dose COVID-19 mRNA vaccination boosts immune responses[2], and observational studies showed three or four-dose vaccine effectiveness (VE) against hospitalisation of 60.9-62.1% against BA.4 or BA.5 and 50.1% against BA.2 when compared to two-doses received ≥25 weeks earlier[3]. These initial COVID-19 vaccines were developed against wild-type virus and provided significant protection against infection, hospitalisation, severe disease and death[4–8]. However, VE has been eroded progressively both by waning of immune-protection over time and emergence of SARS-CoV-2 variants of concern (VOC) (Alpha, Delta, Omicron) which show immune escape[9–12].

In summer 2022, the UK MHRA approved two new bivalent booster vaccines which were developed in response to concerns about such viral evolution and escape. The Moderna bivalent vaccine (Spikevax® bivalent Original/Omicron) was approved on 15th August 2022, followed quickly by Pfizer/BioNTech bivalent vaccine (Comirnaty® Original/Omicron BA.1) approval on 3rd September 2022[13,14]. The Moderna vaccine contains 25mcg of mRNA coding for the spike protein of the ancestral strain and 25mcg of mRNA against Omicron (BA.1) and the Pfizer BioNTech vaccine contains 15mcg of mRNA directed against the ancestral strain and 15mcg of mRNA against Omicron (BA.1). Early immunogenicity studies suggest bivalent mRNA boosters induce similar or higher neutralising antibody levels against Omicron sub-variants and other VOCs compared to monovalent mRNA boosters[15–19]. SARS-CoV-2 infection incidence remains high[20], whilst determining whether patients who test SARS-CoV-2 positive have COVID-19 has become increasingly challenging. Additionally, comparison between vaccinated individuals and those who have not received any COVID-19 vaccine dose cannot be performed, as almost the whole population is vaccinated or had prior exposure to SARS-CoV-2: thus even unvaccinated individuals have some immunity to SARS-CoV-2. There remains an absence of evidence of bivalent vaccines' clinical effectiveness when compared to monovalent formulations because the different vaccine rollout timings make a direct comparison of the vaccines impossible. Acknowledging this constraint, we undertook a testnegative design (TND) case control study comparing SARS-CoV-2 positive and negative acute lower respiratory tract disease (aLRTD) patients, assessing the protection against SARS-CoV-2 hospitalisation provided by an additional monovalent or bivalent mRNA vaccine dose compared

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

- to those who had not received the respective doses, focusing on ≥75y olds who were the main
- target group in the spring 2022 booster programme.

METHODS

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

Study design and conduct

We estimated the relative vaccine effectiveness (rVE) of monovalent and bivalent mRNA vaccines against hospitalisation in Bristol, within the study population consisting of adults admitted to North Bristol and University Hospitals Bristol and Weston NHS Trusts [AvonCAP: ISRCTN17354061] between 4th April 2022 and 30th July 2022 (the period following the initiation of distribution of fourth dose of monovalent mRNA vaccines), and between 21st September 2022 and 23rd January 2023 (the period following the initiation of distribution of bivalent mRNA vaccines) inclusive. During the study period BA.4, BA.2 and BA.5 were the main Omicron sub-lineages identified in COVID-19 cases in Bristol[21]. The study population consisted of patients with signs/symptoms of respiratory infection, aged ≥18y at the time of hospitalisation[22]. Study eligible cases and controls eligible were identified from the medical admission list, and data were collected from medical records using REDCap software[23]. All data collection was undertaken by individuals not involved in analysis and blinded to results, following the same procedures for both cases and controls. Vaccination records for every study participant were obtained from linked hospital and GP records, including vaccine brand and date of administration with data collection performed by individuals blinded to participants' SARS-CoV-2 test results[24].

Case definition and exclusions We included patients with ≥ 2 signs of acute respiratory disease or a confirmed clinical/radiological diagnosis of aLRTD[24]. Patients hospitalised with aLRTD and positive admission SARS-CoV-2 test using the UKHSA diagnostic assay in use at the time were classified as cases; those with aLRTD and negative SARS-CoV-2 result were classified as controls. Eligible controls could have multiple hospitalisations, provided subsequent admissions were >7 days following previous discharge. We included only the first COVID-19 admission for each case. We excluded patients whose admission date was >10 days after symptom onset date (to avoid including potentially false negative admission SARS-CoV-2 tests), and those with a confirmed previous SARS-CoV-2 infection. Patients who had received 2 vaccine doses or fewer at the time of admission were also excluded (Supplementary Data S1). **Exposure definition** This analysis aims to measure the protection offered by an additional dose of monovalent (Original 'wild-type' mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®]) and bivalent (Original 'wild-type'/Omicron BA.1 mRNA vaccine, Pfizer-BioNTech [Comirnaty®] or Moderna [Spikevax®]) vaccine, each compared with those who had not received the respective boosters, side by side, during SARS-CoV-2 Omicron variant dominance. The Spring-Summer monovalent booster analysis (admissions 04/04/22-30/07/22) compares the

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

fourth dose of monovalent given as a booster(21/03/22-07/08/22) in the UK, to the third dose of monovalent vaccine during Autumn-Winter 2021 (16/09/21-14/02/22). The Autumn-Winter bivalent booster analysis (admissions 21/09/22-23/01/23) compares the fifth dose of vaccine, with the bivalent formulation given as a booster (07/09/22-12/02/23) to the fourth dose of monovalent vaccine in Spring-Summer 2022 (21/03/22-07/08/22). For the Spring-Summer monovalent booster analysis, individuals were defined as boosted with a monovalent vaccine if they had received three doses of any monovalent vaccine combination and a fourth dose of monovalent vaccine during the Spring-Summer 2022 vaccination programme, and no more than three months prior to their admission, and as unboosted only if they had received two doses of any vaccine combination followed by a third dose of monovalent vaccine during Autumn-Winter 2021. For the Autumn-Winter bivalent booster analysis, individuals were defined as boosted with a bivalent vaccine if they had received four doses of any vaccine combination plus a fifth bivalent dose during Spring-Summer 2022 vaccination programme and no more than three months prior to their admission, and as unboosted if they had received three doses of any vaccine combination plus a fourth monovalent dose during Autumn-Winter 2022. In both analyses, we define those having received the most recent dose with >7 days having elapsed between the vaccine and symptom onset as immunised (Supplementary Data S1). The Joint Committee on Vaccination and Immunisation (JCVI) advised targeting COVID-19 booster vaccines during spring-summer towards those at highest risk of severe disease; those aged ≥75y and residents in long-term care facilities (LTCFs)[1], while in Autumn-Winter 2022

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

the offer was extended, including those aged ≥ 50 y and frontline health and social care workers[25]. To make a comparison of the effectiveness of the different booster vaccine formulations, we restricted both analyses to individuals aged ≥ 75 y. Individuals who received a third vaccine dose in Autumn-Winter 2021, a fourth dose in Spring-Summer 2022 and a fifth dose in Autumn-Winter 2022, are those who had received two doses as the primary vaccination regimen before and during Spring-Summer 2021. However, individuals with severe immunosuppression around the time of their first or second vaccine doses were offered an additional primary dose (third dose) before any booster doses. As a result, they were offered a fourth vaccine dose in Autumn-Winter 2021, a fifth dose in Spring-Summer 2022 and a sixth dose in Autumn-Winter 2022 (Figure 1, Supplementary Data S2). As additional sensitivity analyses, we included individuals who had received three doses as their primary vaccination regimen in both comparisons. **Outcomes** We assessed the additional protection provided by a fourth dose of mRNA monovalent vaccine and a fifth dose of bivalent vaccine as boosters against the primary endpoint of hospital admission with either a clinical or radiological aLRTD diagnosis or aLRTD signs/symptoms compared to that provided by three or four doses of the monovalent formulations of the vaccines, respectively.

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Statistical Analysis

Demographic, clinical characteristics and other factors that may affect the exposure (vaccination status) or outcome (hospital admission) were compared between cases and controls for both comparisons, between monovalent vaccine boosted and not boosted, and between boosted with a bivalent vaccine and not boosted, using Fisher exact tests (categorical variables), two-sided Kolmogorov-Smirnov tests (continuous variables) and Wilcoxon rank-sum tests (score variables).

Under TND assumptions, we estimate the odds ratio of testing SARS-CoV-2 positive among patients boosted with a monovalent vaccine versus those not boosted (rOR) and define rVE as (1–rOR)×100. Similarly, we estimated rVE of bivalent booster, comparing the odds of testing positive for SARS-CoV-2 among patients boosted with a bivalent vaccine versus those not boosted. This was done using univariable logistic regression (Univariable Logistic Regression Model). Differences in the timing of third/fourth/fifth dose and rollout timings of different vaccine brands could introduce unobserved biases, confounding results in both comparisons. To mitigate these, we performed multivariable logistic regression analyses adjusting for time between baseline vaccine dose and admission (in days), vaccine brand [binary variable], age, gender, Index of Multiple Deprivations (IMD) decile rank and Charlson comorbidity index (CCI) [continuous variable], LTCF residency status, presence of pre-existing respiratory disease, and community SARS-CoV-2 prevalence lagged by time interval between infection and hospitalisation, assumed to be 8-days (Multivariable Logistic Regression Model).

We also conducted sensitivity analyses, matching cases and controls using propensity score balancing using logistic regression to define propensity score, and nearest neighbour matching. Matching variables included age, gender, CCI and IMD, LTCF residency status and presence of pre-existing respiratory disease, and likelihood of vaccine receipt (Matched Conditional Logistic Regression Model). Matching by elapsed time since baseline vaccine dose/brand was not performed to avoid introducing bias[26]. Time since baseline vaccine dose/ brand is affected by dose of last vaccine received; each booster was deployed ≥4 months after the previous COVID-19 booster programme (Figure 1), with different programmes using different proportions of each vaccine brand. As additional sensitivity analysis, we included individuals who had received three doses as primary vaccination regimen, adjusting for the number of primary doses [binary variable], using the same methods for both comparisons. Statistical analyses were performed with R v4.0.2. Missing data were limited to the IMD variable and accounted for <1%; no imputation was performed; all analyses only included participants with complete data. Statistical significance was defined using a 2-sided significance level of $\alpha = 0.05$. **Ethics and permissions** The Health Research Authority Research Ethics Committee (East of England, Essex), REC20/EE/0157 approved this study, including using Section 251 of the 2006 NHS Act under Confidentiality Advisory Group authorisation.

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Role of the funding source

This study was conducted as a collaboration between The University of Bristol (study sponsor) and Pfizer (study funder). The study funder did not undertake any data collection, data analysis or manuscript preparation.

RESULTS

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

During the periods evaluated, 9,868 adult aLRTD hospitalisations occurred in Bristol, UK, while the Omicron variant was dominant[21,27,28]. In the Spring-Summer booster, 864 admissions of ≥75y old patients hospitalised with SARS-CoV-2 aLRTD were eligible for this analysis: median patient age was 85y (IQR 79-90), 96 individuals (53%) were male, median CCI was 5 (IQR 4-6) with no significant differences in patient age, gender, demographics, and health status compared to patients hospitalised with SARS-CoV-2 negative aLRTD (Figure 1, Table 1, Supplementary Data S3). In the Autumn-Winter booster, 884 admissions were eligible with no significant differences in gender, demographics, and health status of study eligible patients admitted with SARS-CoV-2 aLRTD compared to ≥75y old patients hospitalised with SARS-CoV-2 negative aLRTD (Figure 1, Table 2, Supplementary Data S4). In the Spring-Summer booster analysis, of the 182 SARS-CoV-2 cases, 78 (43%) received a fourth monovalent vaccine dose and 104 (57%) received a third monovalent vaccine dose, while 413 of 682 controls (61%) received a fourth monovalent vaccine dose and 269 (39%) received a third monovalent vaccine dose, giving an unadjusted rVE of 51.2% (95%CI 32.1-65). The results from the adjusted logistic regression model indicated that the additional protection against hospitalisation was 46.9% (95%CI 14.4-67.3) when boosted with a fourth monovalent vaccine dose compared to those who received only a third monovalent vaccine dose (Table 3). Matched conditional logistic regression rVE was 52·4% (95%CI 21·4-71·2). Sensitivity analysis including individuals with three doses as primary vaccination regimen resulted in lower rVE estimates compared with results from the main analysis (Table 3, Supplementary Data S5, S6, S9).

In the Autumn-Winter booster analysis, of the 152 SARS-CoV-2 cases, 100 (66%) received a fifth BA.1/ancestral bivalent vaccine dose and 52 (34%) received a fourth monovalent vaccine dose, while 572 of 732 (78%) controls received a fifth bivalent vaccine dose and 160 (22%) received a fourth monovalent vaccine dose, giving an unadjusted rVE of 46·2% (95%CI 21·1-63). According to the adjusted logistic regression model, the adjusted rVE of a fifth bivalent vaccine dose as a booster compared to a fourth monovalent vaccine dose was 46·4% (95%CI 17·5-65). Matched conditional logistic regression rVE was 48·5% (95%CI 19·3-67·1) (Table 4). The inclusion of individuals with three doses as primary vaccination regimen produced estimates comparable with results from the main analysis (Table 4, Supplementary Data S7, S8, S10).

DISCUSSION

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

In this analysis, we consider the public health implications of monovalent and bivalent vaccine implementation, focusing on people aged ≥75y; a high-risk group which was a primary target for the UK vaccination programme. Although COVID-19 vaccines have been shown to be effective against severe COVID-19 disease[4,29,30], it has not been possible to compare the effectiveness of monovalent boosters directly with BA.1/ancestral bivalent booster doses of mRNA COVID-19 vaccines in defined populations, because bivalent formulations rapidly and entirely replaced monovalent formulations in the most recent booster programmes. In this prospective study, we undertake a sequential analysis of the two vaccines given as boosters during two booster programmes in the same calendar year, providing evidence that monovalent vaccine (Original 'wild-type' Comirnaty® and Spikevax®) and BA.1/ancestral mRNA bivalent vaccine (Original 'wild-type'/Omicron BA.1 Cominarty® and SpikeVax®) provided similar additional protection over and above that afforded by previous doses without the respective boosters against hospitalisation from Omicron SARS-CoV-2 sub-variants in older individuals. Specifically, we estimated that receiving a fourth monovalent mRNA vaccine dose within three months was associated with a 46.9% (95% CI 14.4-67.3) relative reduction in hospitalisation risk compared to three doses, in individuals ≥75y, during Omicron BA.2/BA.4/BA.5 lineage dominance. A fifth bivalent mRNA vaccine dose given within three months is estimated to provide 46.4% (95%CI 17.5-65) additional protection against hospitalisation compared to four doses, in the same ≥75y age group, during a period in which alongside Omicron BA.2/BA.4/BA.5 related sublineages, the XBB recombinant lineage and its mutation XBB.1.5

emerged [27]. Although our results demonstrate that both vaccine formulations combined in these booster programmes had benefits when used as boosters, we have insufficient case numbers to draw conclusions about individual vaccine brands or directly compare them. Importantly, this analysis is restricted to individuals ≥75y old, with 97-98% of unboosted individuals in our sample having received their last dose more than 3 months prior to admission (Supplementary Data S2), and provides encouraging evidence of similar benefit of monovalent and bivalent boosters in older adults. Older adults are at increased risk of severe disease, and protection may wane faster[31]; older adults were therefore targeted in the UK Spring-Summer 2022 and Autumn-Winter 2022 COVID-19 booster programmes. Regarding individuals with severely weakened immune systems who were eligible for three primary doses, our analysis based on their inclusion in our basic comparisons, suggests that both vaccine formulations may offer some additional protection.

Vaccination against SARS-CoV-2 is independently associated with lower COVID-19 severity[4,29,30], and vaccines have been an important disease modifier during the pandemic. Our estimates suggest that the bivalent boosters provided equivalent protection as monovalent boosters in a real-world setting: results concordant with early evidence suggesting neutralising antibody titres induced against Omicron by a bivalent booster dose were not higher than following a monovalent booster dose in small studies[16,17]. Our results are concordant with a recent UKHSA analysis[32] which estimated the incremental protection conferred by a fourth monovalent dose compared to waned third dose was 58.8% (95%CI 54-63%), while the additional protection of BA.1/ancestral mRNA bivalent vaccines relative to those with ≥2 doses and waned protection was 57% (95%CI 48-65%), during the same time period as our analysis.

Since the study took place over the course of two different time periods, the interpretation of this sequential comparison of the two vaccine formulations has to take into account the different variants circulating[21,27,28]. Currently, there is no evidence that Omicron BA.2-related sublineages, Omicron BA.5-related sublineages and XBB recombinant-related sublineages, which appeared during the study period of the BA.1/ancestral mRNA bivalent boosters, cause more severe disease. The impact of these lineages on the effectiveness of the BA.1/ancestral mRNA bivalent formulation has not yet been studied in detail. The TND has been described previously, along with its advantages and limitations [12,24,33], and our analysis has some important additional strengths and limitations. The strength of our approach is the focus on using real-world data, while accounting for the potential effects of vaccine waning, and comorbidities. By limiting our analysis to boosted individuals only, our analysis sidesteps the potentially unfair comparisons between populations that have followed UK COVID-19 vaccine recommendations and unvaccinated populations that may display other idiosyncratic behaviours. We also utilised symptom onset date to define illness start time and are able to confirm that there is no difference in time since vaccination between the case and control groups compared. We, therefore, define illness onset relative to both vaccination and hospitalisation date accurately, without relying on positive test date (which may vary widely), eliminating this source of bias or misclassification. All patients were hospitalised with acute respiratory illness, so these results are unlikely to be subject to significant bias caused by admission for other causes (i.e., incidental COVID-19 disease). Most notably, our estimates for

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

the effect of individual vaccines are underpowered, due to small patient numbers in our cohort during the phases of the UK vaccination programme and study periods. We are unable to assess additional protection against other markers of disease severity, such as admission to intensive care or requirement for respiratory support, due to the small number of eligible admissions in this time period. This analysis does not measure rVE in individuals who were not hospitalised or were asymptomatic, so we cannot determine protection against asymptomatic disease or transmission. Treatment biases may result in community-based treatment, death before admission, or patients may otherwise not be referred to hospital. We note that this cohort, whilst broadly representative of the UK population, was predominantly Caucasian and the studied vaccines may have different effectiveness in individuals from other ethnic backgrounds. In this prospective study, we provide evidence that autumn BA.1/ancestral mRNA bivalent COVID-19 boosters offered equivalent augmentation of protection against Omicron hospitalisation to that induced by spring monovalent mRNA boosters in 2022. Our findings support the current UK immunisation programme, that advises the use of bivalent booster doses in high-risk individuals.

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

FIGURE LEGENDS

monovalent mRNA vaccine. (B) Study timeline

Figure One: Study Flow Diagram

(A) Inclusion and exclusion criteria in the cohort. Of the 55 SARS-CoV-2 positive individuals,

33 were vaccinated with 5/6th dose bivalent mRNA vaccine, and 22 were vaccinated with 5/6th

dose monovalent mRNA vaccine. Of the 350 SARS-CoV-2 negative individuals admitted, 269

were vaccinated with 5/6th dose bivalent mRNA vaccine and 81 were vaccinated with 5/6th dose

Data Sharing The data used in this study are sensitive and cannot be made publicly available without breaching patient confidentiality rules. The data dictionary is therefore unavailable. **Contributors** AC, CH, RC, RM, LD, JO, and AF generated the research questions and analysis plan. CH, JK, JK, MC, DA and The AvonCAP team were involved in data collection. AC, CH, RM, RC, LD, and AF undertook data analysis. All authors (AC, CH, RC, RM, JK, DA, JK, MC, NM, JO, LD, AF) were involved in the final manuscript preparation and its revisions before publication. The data was verified by CH, DA, MC, JK and JK. AF provided oversight of the research. **Declarations of Interest** CH is Principal Investigator of the AvonCAP study which is an investigator-led University of Bristol study funded by Pfizer and has previously received support from the NIHR in an Academic Clinical Fellowship. JO and LD are Co-Investigators on the AvonCAP Study. AF is a member of the Joint Committee on Vaccination and Immunization (JCVI) and, until December 2022 was chair of the World Health Organization European Technical Advisory Group of Experts on Immunization (ETAGE) committee. In addition to receiving funding from Pfizer as Chief Investigator of this study, he leads another project investigating transmission of respiratory

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

bacteria in families jointly funded by Pfizer and the Gates Foundation. The other authors have no relevant conflicts of interest to declare. Acknowledgements We thank Jennifer Nguyen, Joanna Southern, Bradford Gessner, John McLaughlin, Gillian Ellsbury, Kaijie Pan, Luis Jodar, Elizabeth Begier, the UKHSA Vaccine Effectiveness Working Group and the University of Bristol UNCOVER group for guidance in study design and data analysis. We thank colleagues for their support with this study, including Rachel Davies, Paul Savage, Emma Foose, Susan Christie, Mark Mummé, and Adam Taylor. We also thank the research teams at North Bristol and University Hospitals of Bristol and Weston NHS Trusts for making this study possible, including Helen Lewis-White, Rebecca Smith, Rajeka Lazarus, Mark Lyttle, Kelly Turner, Jane Blazeby, Diana Benton, and David Wynick and all participants of the many studies undertaken to find effective vaccines against SARS-CoV-2. LD and RC gratefully acknowledge support from UKRI through the JUNIPER consortium (grant number MR/V038613/1). LD is further supported through MRC (grant number MC/PC/19067), EPSRC (EP/V051555/1). The AvonCAP Research Group:

Anna Morley, Amelia Langdon, Anabella Turner, Anya Mattocks, Bethany Osborne, Charli

Grimes, Claire Mitchell, David Adegbite, Emma Bridgeman, Emma Scott, Fiona Perkins,

Francesca Bayley, Gabriella Ruffino, Gabriella Valentine, Grace Tilzey, James Campling,

23

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

Johanna Kellett Wright, Julia Brzezinska, Julie Cloake, Katarina Milutinovic, Kate Helliker, Katie Maughan, Kazminder Fox, Konstantina Minou, Lana Ward, Leah Fleming, Leigh Morrison, Lily Smart, Louise Wright, Lucy Grimwood, Maddalena Bellavia, Madeleine Clout, Marianne Vasquez, Maria Garcia Gonzalez, Milo Jeenes-Flanagan, Natalie Chang, Niall Grace, Nicola Manning, Oliver Griffiths, Pip Croxford, Peter Sequenza, Rajeka Lazarus, Rhian Walters, Robin Marlow, Robyn Heath, Rupert Antico, Sandi Nammuni Arachchge, Seevakumar Suppiah, Taslima Mona, Tawassal Riaz, Vicki Mackay, Zandile Maseko, Zoe Taylor, Zsolt Friedrich, Zsuzsa Szasz-Benczur.

REFERENCES

- 1. Joint Committee on Vaccination and Immunisation (JCVI) statement on COVID-19
- vaccinations in 2022: 21 February 2022. https://www.gov.uk/government/publications/joint-
- 416 committee-on-vaccination-and-immunisation-statement-on-covid-19-vaccinations-in-2022/joint-
- 417 committee-on-vaccination-and-immunisation-jcvi-statement-on-covid-19-vaccinations-in-2022-
- 418 21-february-2022.
- 2. Munro APS, Feng S, Janani L, Cornelius V, Aley PK, Babbage G, et al. Safety,
- 420 immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given
- as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third
- dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. Lancet
- 423 Infect Dis. 2022;22:1131–41.
- 3. Kirsebom FCM, Andrews N, Stowe J, Groves N, Chand M, Ramsay M, et al. Effectiveness of
- 425 the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in
- 426 England. Lancet Reg Health Eur. Elsevier; 2022;23.
- 427 4. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T, et al. Clinical
- 428 severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and
- alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. British
- 430 Medical Journal Publishing Group; 2022;376:e069761.
- 5. Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9
- 432 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study
- 433 in Sweden. Lancet Lond Engl. 2022;399:814–23.
- 6. Chung H, He S, Nasreen S, Sundaram ME, Buchan SA, Wilson SE, et al. Effectiveness of
- 435 BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and
- 436 severe covid-19 outcomes in Ontario, Canada: test negative design study. BMJ. British Medical
- Journal Publishing Group; 2021;374:n1943.
- 438 7. Andrews N, Stowe J, Kirsebom F, Toffa S, Sachdeva R, Gower C, et al. Effectiveness of
- 439 COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in
- 440 England. Nat Med. 2022;28:831–7.
- 8. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-
- 442 1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28:1063–71.
- 9. Britton A, Fleming-Dutra KE, Shang N, Smith ZR, Dorji T, Derado G, et al. Association of
- 444 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination
- and Delta Variant Predominance. JAMA. 2022;327:1032–41.
- 446 10. Lin D-Y, Gu Y, Xu Y, Wheeler B, Young H, Sunny SK, et al. Association of Primary and
- 447 Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19
- 448 Outcomes. JAMA. 2022;328:1415–26.

- 11. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, et al. Waning 2-
- 450 Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency
- 451 Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of
- 452 Delta and Omicron Variant Predominance VISION Network, 10 States, August 2021-January
- 453 2022. MMWR Morb Mortal Wkly Rep. 2022;71:255–63.
- 454 12. Andrews N, Tessier E, Stowe J, Gower C, Kirsebom F, Simmons R, et al. Duration of
- 455 Protection against Mild and Severe Disease by Covid-19 Vaccines. N Engl J Med.
- 456 2022;386:340–50.
- 457 13. Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine.
- 458 https://www.gov.uk/government/publications/regulatory-approval-of-spikevax-bivalent-
- 459 originalomicron-booster-vaccine.
- 460 14. Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines.
- 461 https://www.gov.uk/government/publications/regulatory-approval-of-pfizerbiontech-bivalent-
- 462 originalomicron-booster-vaccine.
- 463 15. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A Bivalent Omicron-
- 464 Containing Booster Vaccine against Covid-19. N Engl J Med. 2022;387:1279–91.
- 16. Collier AY, Miller J, Hachmann NP, McMahan K, Liu J, Bondzie EA, et al. Immunogenicity
- of the BA.5 Bivalent mRNA Vaccine Boosters. bioRxiv. 2022;2022.10.24.513619.
- 467 17. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L, et al. Antibody responses to
- Omicron BA.4/BA.5 bivalent mRNA vaccine booster shot. bioRxiv. 2022;2022.10.22.513349.
- 469 18. Davis-Gardner ME, Lai L, Wali B, Samaha H, Solis D, Lee M, et al. mRNA bivalent booster
- 470 enhances neutralization against BA.2.75.2 and BQ.1.1. bioRxiv. 2022;2022.10.31.514636.
- 19. Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralization of SARS-CoV-
- 2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent
- 473 booster. Nat Med. 2022;1–1.
- 20. England Summary | Coronavirus (COVID-19) in the UK. https://coronavirus.data.gov.uk.
- 475 2023.
- 476 21. Lineages (raw) | COVID-19 Genomic Surveillance Wellcome Sanger Institute.
- 477 https://covid19.sanger.ac.uk/lineages/raw?p_type=line&area=E06000023&lineageView=1&line
- 478 ages=A%2CB%2CB.1.177%2CB.1.1.529%2CBA.4%2CBA.5%2CBA.2&colours=7%2C3%2C
- 479 0%2C6%2C2%2C4%2C1&show=B.1.1.529%2CBA.4%2CBA.5%2CBA.2.
- 480 22. Hyams C, Challen R, Begier E, Southern J, King J, Morley A, et al. Incidence of community
- acquired lower respiratory tract disease in Bristol, UK during the COVID-19 pandemic: A
- prospective cohort study. Lancet Reg Health Eur. Elsevier; 2022;21.

- 483 23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data
- 484 capture (REDCap)—A metadata-driven methodology and workflow process for providing
- translational research informatics support. J Biomed Inform. 2009;42:377–81.
- 486 24. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Effectiveness of BNT162b2
- and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at
- least 80 years: a test-negative, case-control study. Lancet Infect Dis. Elsevier; 2021;21:1539–48.
- 489 25. JCVI statement on the COVID-19 booster vaccination programme for autumn 2022: update 3
- 490 September 2022. https://www.gov.uk/government/publications/covid-19-vaccines-for-autumn-
- 491 2022-jcvi-advice-15-august-2022/jcvi-statement-on-the-covid-19-booster-vaccination-
- 492 programme-for-autumn-2022-update-15-august-2022.
- 493 26. Greenland S. Quantifying biases in causal models: classical confounding vs collider-
- 494 stratification bias. Epidemiol Camb Mass. 2003;14:300–6.
- 495 27. SARS-CoV-2 variants of concern and variants under investigation in England: Technical
- 496 briefing 50.
- 497 28. Wright DW, Harvey WT, Hughes J, Cox M, Peacock TP, Colquhoun R, et al. Tracking
- 498 SARS-CoV-2 mutations and variants through the COG-UK-Mutation Explorer. Virus Evol.
- 499 2022;8:veac023.
- 500 29. Hyams C, Challen R, Marlow R, Nguyen J, Begier E, Southern J, et al. Severity of Omicron
- 501 (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A
- prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556.
- 503 30. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
- analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron
- 505 (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet.
- 506 2022;399:1303–12.
- 31. Cerqueira-Silva T, Oliveira V de A, Boaventura VS, Pescarini JM, Júnior JB, Machado TM,
- et al. Influence of age on the effectiveness and duration of protection of Vaxzevria and
- 509 CoronaVac vaccines: A population-based study. Lancet Reg Health Am. Elsevier; 2022;6.
- 510 32. COVID-19 vaccine surveillance report: week 5.
- 511 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file
- 512 /1134076/vaccine-surveillance-report-week-5-2023.pdf.
- 33. Chatzilena A, Hyams C, Challen R, Marlow R, King J, Adegbite D, et al. Effectiveness of
- 514 BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults
- with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and
- 516 July 2022: A prospective test negative case–control study. Lancet Reg Health Eur.
- 517 2023;25:100552.



